Boston Scientific Corporation (NYSE: BSX) has successfully implemented the first cases in the United States using the FDA-approved Farapulse pulsed field ablation system.

The Farapulse system includes the Farawave ablation catheter, Farastar ablation generator, and Faradrive steerable sheath. [Image source: Boston Scientific]

Boston Scientific's Vice President of Arrhythmia Division, Nick Spadea-Anello, announced on LinkedIn the first commercial use of the company’s Farapulse system for atrial fibrillation treatment. Boston Scientific Corporation, based in Marlborough, Massachusetts, received approval for Farapulse last month.

This makes Boston Scientific the second company, after Medtronic, to receive FDA approval for using PFA (Pulsed Field Ablation) technology to treat atrial fibrillation. Medtronic received the first approval for PFA to treat paroxysmal and persistent atrial fibrillation in December of last year. The approval allows the use of Farapulse for pulmonary vein isolation in patients with drug-refractory, recurrent, symptomatic paroxysmal atrial fibrillation.

Spadea-Anello wrote on the social media site: "Today, doctors across the United States are able to see and feel how this new therapy has the potential to transform the field of ablation and provide a safe, effective, and efficient treatment option for patients with paroxysmal [atrial fibrillation]."

Spadea-Anello noted that the doctors completed more than 30 commercial cases on Thursday, February 15. He specifically mentioned Dr. Andrea Natale and his team from Los Robles, as well as Dr. Wilbur Su and Dr. Roderick Tung and their teams from Banner Health, all of whom he had the opportunity to observe.

He concluded: "Thank you to everyone who has contributed to achieving this milestone. I look forward to continuing our collaboration to improve the lives of patients with paroxysmal [atrial fibrillation] in the United States and around the world."